Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Aug 2017

Golan Talia, Javle Milind

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a 5-year survival rate of ≤7% across all stages. The limited success of conventional therapies for PDAC is at least partially attributable to its genetic heterogeneity. Precision targeting of known PDAC subtypes may positively affect the outcome of this disease. An important actionable subtype in this cancer is associated with DNA repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to DNA Repair
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to Germ-Line Mutation

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Pancreatic Neoplasms

Source

Identifiers

PMID: 28784866
DOI: 10.6004/jnccn.2017.0133

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.PMID 28784866Read ↗

Germline Aberrations in Pancreatic Cancer: Implications for Clinical CareSemantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Targeting DNA Damage Repair Mechanisms in Pancreas CancerSemantic proximity Read ↗

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsSemantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

Recent advances in precision medicine for pancreatic ductal adenocarcinomaSemantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

Germline mutations in pancreatic cancer and potential new therapeutic optionsSemantic proximity Read ↗

An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.